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Summary In DNA digested samples of a CDDP sensitive (GLC4) and an 11-fold resistant (GLC4-CDDP)
hSCLC line, the CDDP induced DNA adducts Pt-GG (Pt-(NH3)2d (pGpG)), Pt-AG (Pt-(NH3)2d (pApG)),
G-Pt-G (Pt-(NH3)2d (GMP)2) and Pt-GMP (Pt-(NH3)3d GMP), were measured with polyclonal antibodies. The
total amount of platinum (Pt) bound to DNA was also measured but with the help of atomic absorption
spectroscopy (AAS). An increased net formation in GLC4 compared with GLC4-CDDP is found for the total
Pt bound to DNA, Pt-GG and Pt-AG adducts after a 2 h 100 pM CDDP treatment. No significant difference
is detected in the net formation of the Pt-GMP and G-Pt-G adducts. A slow Pt-AG adduct formation, with a
maximum reached 10 h after CDDP composition, is found for both cell lines. In the 22 h period after the 2 h
1001iM CDDP treatment, a significant removal in GLC4 is measured for the Pt-GG, Pt-AG and the Pt-GMP
adducts. For GLC4-CDDP a significant removal is detected in the total Pt bound to DNA, the Pt-AG and the
Pt-GMP adducts. The removal of the total Pt bound to DNA in GLC4-CDDP cannot be explained by an
adduct measured with the immunochemical method. In conclusion, no evidence is found that CDDP resistance
is based upon the repair of the Pt-GG, Pt-AG, G-Pt-G and Pt-GMP adducts.
The application of CDDP is hampered by the presence of
initial resistance in many prevalent tumour types and because
of the development of acquired resistance in tumours that are
initially sensitive. Although CDDP can react with many
structures in the cell, such as membranes (Scanlon et al.,
1983), proteins and RNA, the most important target is.
presumed to be the DNA (Roberts et al., 1986). The recent
development of polyclonal antibodies to the various platina-
tion products of the DNA (Fichtinger-Schepman et al., 1987)
has facilitated the study of the relationship between the
formation and removal of adducts and the occurrence of
CDDP resistance. With this technique we have studied the
formation of Pt-GG, Pt-AG, Pt-GMP and G-Pt-G adducts,
as well as the total amount of Pt bound to the DNA (which
is measured by AAS). In addition, the persistence of the
various modes of platination was measured in a period of
22 h following a 2 h CDDP exposure.
The cell line used for these experiments is a recently des-
cribed hSCLC cell line GLC4 and the CDDP resistant subline
GLC4-CDDP (Hospers et al., 1988).
Materials and methods
Chemicals
CDDP was provided by Bristol Myers SAE (Madrid, Spain).
Roswell Park Memorial Institute (RPMI) 1640 was obtained
from Gibco (Paisley, Scotland), fetal calf serum (FCS) from
Flow Lab. (Irvine, Scotland), 3-(4,5-dimethyl-thiazol-2-yl)-
2,5-diphenyltetrazoliumbromide (MTT) from Sigma (St
Louis, USA) and dimethyl sulphoxide from Merck (Darm-
stadt, FRG). 3H-thymidine was supplied by New England
Nuclear (Boston, USA).
Cell culture
GLC4-CDDP is a subline of GLC4 with an acquired resis-
tance for CDDP with a resistance factor (RF) of 11. The
doubling time for GLC4 and GLC4-CDDP is 24 and 43 h,
respectively. Both cell lines are growing partly in suspension
and partly attached in RPMI 1640, 10% FCS in a humidified
atmosphere with 5% CO2 at 37°C. The cell line has been
described when it had a resistance factor of 6.4 (Hospers et
al., 1988). It has been kept exposed to CDDP since, leading
to an increase in RF of 11 that has remained unchanged over
the last year. Growth characteristics and total GSH levels
have remained unchanged despite the increase in RF.
Microculture tetrazolium assay (MTA)
The microculture tetrazolium assay is dependent on the cel-
lular reduction of MTT to a blue formazan product. This
reduction is caused by the mitochondrial dehydrogenase of
viable cells and can be measured spectrophotometrically
(Carmichael et al., 1987). Before the assays were performed,
the relationship of cell number to MTT formazan crystal
formation was checked and cell growth studies were per-
formed. The culture period leading to two to three cell
divisions was chosen. Per microculture well (96-well micro-
titre plates, Nunc, Gibco, Paisley, Scotland) a total volume
of 0.1 ml was used. For GLC4, 5,000 cells per well and for
GLC4-CDDP, 15,000 cells per well were incubated for 2 h in
RPMI, 10% FSC, with 1-250 1M CDDP. Cells need not be
brought into single cell suspension for this assay. After 2 h,
the cells were washed three times by removing the medium
after centrifugation (Omin, 150g) followed by addition of
fresh medium. After a culture period of 4 days, 20 of a
5 mg ml-' MTT in phosphate buffered saline (PBS) solution
was added to each well. Plates were then centrifuged (30 min,
150g). The supernatant was aspirated, taking special care
not to disturb the formazan crystals. Dimethyl sulphoxide
(100%, 200 pA) was used to solubilise the formazan crystals
and the plate was read immediately at 520 nm using a scann-
ing microtitre well spectrophotometer (Flow Lab, Irvine,
Scotland). Surviving fraction was calculated by the equation
mean of test sample/mean of untreated sample. Controls
consisted of media without cells (background extinction), and
cells incubated in microculture wells with medium without
the drug. Four experiments were performed in triplicate.
Trypan blue exclusion test
Cell survival, until 22 h after CDDP exposure, was checked
with trypan blue exclusion (0.4% trypan blue solution in PBS
diluted 1: 1 with a cellular suspension).
CDDP treatmentfor the study ofPt-DNA effects
Cells (5 x I0) were treated with 100 gM CDDP in 50 ml
medium (RPMI with 10% FCS). Cells were harvested for
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Pt-DNA binding experiments by AAS and the
immunochemical quantitation of Pt-DNA adducts in DNA
digested samples during the CDDP treatment (at I and 2 h)
and after the 2 h CDDP treatment at 4, 10 and 22 h.
After a 2 h CDDP treatment, cells were washed twice with
PBS (37°C) and resuspended for further culture in fresh
medium at 37°C. For the repair period t = 0 h the cells were
resuspended in fresh medium at 0°C. After a repair period
(t = 0 h, t = 4 h, t = 22 h) the cells were washed twice with
PBS (0°C), pelleted by centrifugation and frozen. For the I h
CDDP treated cells, the cells were washed twice with PBS
(0°C), once with fresh medium (0°C and again twice with
PBS (0°C), pelleted by centrifugation and frozen (- 20°C).
These five washings in the 1 h CDDP treated cells were
performed in order to be able to compare the results of the I
and 2 h CDDP treatments. Two separate experiments were
performed.
DNA synthesis
The DNA synthesis was measured in GLC4 and GLC4-
CDDP after a 2 h 100 fLM CDDP exposure as described by
Bedford et al. (1988), with minor modifications.
Briefly, cells were labelled for 24h with 0.20plCimnl'3H-
thymidine followed by 4 h in isotope free medium. Cells were
exposed for 2 h to 1000tM CDDP and harvested at 0, 4, 10
and 22 h. DNA was extracted by heating cell pellets at 70°C
for I h in 1 N perchloric acid. The 3H radioactivity was
determined by scintillation counting and the DNA content
was estimated spectrophotometrically at 260 nm. The dilution
factor was calculated by dividing the specific activity of DNA
at 4, 10 or 22 h by the specific activity of DNA at 0 h. Two
experiments were performed in duplicate.
DNA isolation
The DNA from frozen pellets (5 x I07cells) was isolated as
described by Fichtinger-Schepman et al. (1987). Briefly, a
phenol extraction and ethanol precipitation was followed by
a RNase treatment. The remaining proteins were extracted
by chloroform/isoamylalcohol.
Quantitation of total Pt bound to DNA
After DNA isolation (5 x I07 cells) the DNA was solubilised
in 1 M HCI. The DNA content was measured spectro-
photometrically at 260 nm (extinction of 1 mg
DNA ml-'= 27). The Pt content was determined by ASS
(Varian Techtron Pty Ltd, Mulgrave, Victoria, Australia)
(Hospers et al., 1988). The two different experiments were
performed each in duplicate.
Immunochemical quantitation of Pt-DNA adducts
The Pt-GG, Pt-AG, Pt-GMP and G-Pt-G adducts were
measured using three different polyclonal antibodies accord-
ing to Fichtinger-Schepman et al. (1987). After DNA isola-
tion and digestion, the DNA products were separated on the
Mono Q column (Pharmacia, Sweden). After preparing a
standard curve with DNA of the cells, the total DNA con-
tent was determined from the dGMP peak height of the high
performance liquid chromatography pattern. The content of
the different adducts in the eluate fraction was determined in
a competitive enzyme linked immunosorbent assay (ELISA).
The two different experiments were each performed in three
different competitive ELISAs and each ELISA was per-
formed in four dilutions in duplicate.
Statistical analysis
Differences were tested using the paired and unpaired
Student's t test with P <0.05 considered as significant.
Error bars in Figures 1-3 are given for cumulative data in
repeat experiments.
Results
Survival
No cell loss or loss in viability for both cell lines, as tested
with the trypan blue assay, was detected 22 h after CDDP
treatment in the concentrations used.
Figure 1 shows the dose-response curves for CDDP treat-
ment in GLC4 and GLC4-CDDP as tested in the MTA assay.
GLC4-CDDP had a RF of 11 based on the IC50, the dose
inhibiting cell survival by 50%. Thirty per cent of GLC4-
CDDP cells survived 72 h after a 2 h exposure to 100 JIM
CDDP.
Formation and removal ofCDDP induced Pt-DNA adducts
During the period after the end of the CDDP treatment, a
decrease in the adduct content per DNA amount could be
due to either removal or DNA synthesis. The aim of this
study was to measure the removal and therefore all presented
data are corrected for DNA synthesis. The dilution factor for
GLC4 at 4, 10 and 22 h post-CDDP treatment was
0.93 ± 0.03 (s.e.), 0.89 ± 0.02 and 0.83 ± 0.03, respectively.
The dilution factor for GLC4-CDDP at 4, 10 and 22 h
post-CDDP treatment was 0.94 ± 0.02, 0.91 ± 0.02 and
0.86 ± 0.01, respectively.
Figure 2 shows the Pt-DNA adduct formation and
removal in GLC4 and GLC4-CDDP. During the last hour of
the CDDP treatment, there was an equal net Pt-DNA form-
ation rate. The net formation was higher at the end of the
incubation in GLC4, suggesting a more rapid net platination
at the beginning. In the post-treatment period there was a
significant repair from 0 to 4 h in the GLC4-CDDP (approxi-
mately 20% reduction) and no repair in GLC4. After 4 h, no
further reduction of Pt-DNA was seen in GLC4-CDDP.
Figure 3 shows the Pt-GG, Pt-AG, G-Pt-G and Pt-GMP
adduct formation and removal in GLC4 and GLC4-CDDP.
There was a higher net Pt-GG formation rate during CDDP
treatment in GLC4. While there was a significant removal
over a 4 h period (approximately 30% reduction) seen in
GLC4, no removal was seen in GLC4-CDDP. The Pt-AG
adduct formation was, in contrast to other adducts, formed
to a large degree after exposure to CDDP has been com-
pleted. Pt-AG adduct formation was slow. Its maximum was
reached after 10 h post-treatment. After 10 h there was
significant Pt-AG repair in both cell lines. The G-Pt-G
adduct showed a slower net adduct formation rate in GLC4-
CDDP. No significant repair was found for both cell lines.
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Figure I Cytotoxicity with MTA after 2 h incubation with
CDDP with GLC4 (0-0) and GLC4-CDDP (0-*). Bars s.e.
(n = 7- 12). Statistics GLC4 versus GLC4-CDDP: D, P <0.0005.CDDP INDUCED DNA ADDUCTS IN CDDP RESISTANT CELLS 81
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Figure 2 Pt-DNA binding after 1 and 2 h 100gM CDDP treat-
ment. After 2 h 100JAM CDDP treatment the Pt-DNA binding, in
GLC4 (0-0) and GLC4-CDDP (@-), is given as a function of
length of a post-treatment incubation period. Bars s.e. (n = 4).
Statistics GLC)4 versus GLC4-CDDP: D, P <0.0005. (-0)
decrease (C).
The Pt-GMP adduct showed a significant difference in for-
mation after the first h CDDP treatment. No difference was
found after 2 h CDDP treatment. A significant but equal
Pt-GMP adduct removal was found in both cell lines.
The distribution of the adducts is shown in Table I. The
major adduct was the Pt-GG in both cell lines. There was an
increased percentage of the Pt-GG adducts in GLC4 at each
time point and a decreased percentage of the Pt-AG and
G-Pt-G adducts as compared with GLC4-CDDP.
Discussion
The spectrum of adducts found between CDDP and DNA
(Pt-GG, Pt-AG, Pt-GMP and G-Pt-G) does not differ
between isolated DNA and various cell types (Fichtinger-
Schepman et al., 1985, 1987, 1988; Bedford et al., 1988;
Plooy et al., 1985). However, quantitative differences exist
Table I Distribution of adducts as a percentage of total platination
in GLC4 and GLC4-CDDP after I and 2 h 100tLM CDDP treatment,
and 10 and 22 following the 2 h 1I00 JM CDDP exposure
GLC4 GLC4-CDDP
Amount as % of total platination
Pt-GG
-I h 69 48
Oh 79 51
10h 61 58
22h 75 60
Pt-AG
-lh 19 33
Oh 10 23
10h 27 28
22 h 15 26
G-Pt-G
-lh 5 13
Oh 5 12
10h 8 10
22h 9 12
Pt-GMP
-lh 7 5
Oh 6 15
lOh 4 n.d.
22h 2 2
Amount (fmol Ptpg` DNA) ±s.e.
Total0
-1 h 54±3.4 33±4.6
Oh 282±30 102 11
lOh 244±17 148±21
22h 214 19 85±20
'Total binding was calculated by adding together the amounts of
the four individual adducts measured by the immunochemical
method.
between adducts found in different cell lines with widely
different sensitivity for cisplatin (Fichtinger-Schepman et al.,
1988). Therefore, the study of the kinetics of adduct forma-
tion could be relevant for the problem of CDDP resistance.
Eastman et al. (1988) found a relationship between the Pt-
GG adduct repair and the RF in murine leukaemia L1210
cells. These Pt-GG adducts are induced by (3H)-cis-
dichloro(ethylene-diamine)platinum (II) (cis-DEP), a CDDP
analogue. In this experiment, we studied the formation and
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Figure 3 Pt-GG, Pt-AG, G-Pt-G and Pt-GMP adduct content after I h and 2 h 100 JAM CDDP treatment. After 2 h I100 uM
CDDP treatment the Pt-GG, Pt-Ag, G-Pt-G and Pt-GMP adduct content, in GLC4 (0-0) and GLC4-CDDP (- 0) is given as a
function of length of a post-treatment incubation period. Bars s.e. (n = 3-6). Statistics GLC4 versus GLC4-CDDP: B, P <0.05; C,
P <0.005; D, P <0.0005. Pt-GG: 0-0 decrease (C). Pt-AG: 0 -0/0-0 t = 10 h increase (B). G-Pt-G: 0-0/0-0 increase
- 1 to 0 h (C). Pt-GMP: 0-0/0-0 increase - I to 0 h (C), 0-0/0 - decrease 0 to 4 h (D).
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repair of the CDDP induced DNA adducts: Pt-GG, Pt-AG,
Pt-GMP and G-Pt-G, in a CDDP resistant and sensitive
human SCLC cell line with the help of polyclonal antibodies.
In a previous experiment on the platination of GLC4 and
its CDDP resistant subline GLC4-CDDP (Hospers et al.,
1988) we described a difference in formation of interstrand
cross-links, but not in Pt-GG adducts as is found in the
experiments described here. This difference, though possibly
influenced by a somewhat higher CDDP concentration used,
1I00 IM now versus 67 JiM maximum previously, may more
probably be due to a more important factor, that being the
substantial increase in resistance (RF 11 versus 6.4). These
observations underline the importance of the degree of resis-
tance in studies on resistance mechanisms.
Adding to our previous observations of differences in the
formation of total platination and interstrand cross-links
between sensitive and resistant cells, we now also detect
differences in Pt-GG and Pt-AG adduct formation. Total
platination occurs more rapidly in the sensitive line, and total
Pt-GG adduct formation is 68% higher at the end of the
CDDP exposition.
The difference in the quantitatively important Pt-GG
adducts is more likely to correspond to resistance than the
difference in the formation of Pt-AG adducts. Although the
Pt-AG adducts can be cytotoxic, or at least mutagenic (Burn-
ouf et al., 1987) a form of repair equalises the differences in
sensitive and resistant cells as far as Pt-AG adducts are
concerned. It is not clear why these adducts can be formed in
the hours after exposition. Their number is too high to be
explained by monoadduct conversion only. They may be the
result of residual free CDDP, but no difference in cellular
and nuclear Pt concentration was found (Hospers et al.,
1988) to explain the differences in kinetics.
This lack of differences in Pt concentrations also suggests
that differences in the net formation of Pt-DNA adducts
between both cell lines is most likely due either to differences
in repair of adducts or to differences at the DNA level; for
instance, in the conformational state of the DNA. As far as
the Pt-GG adducts are concerned, the lack of evidence for
their repair in the GLC4-CDDP cell line favours the role of a
DNA factor. Repair does seem to be present in GLC4-CDDP
as far as the total platination is concerned (Figure 2). From
the adducts measured in this study with the immunochemical
method none can explain this decrease in platination during
the first 4 h after exposition as measured by the AAS
(Figure 2), especially in view of the minute quantitative role
of adducts other than Pt-GG. We suggest that some adduct
is formed in the resistant cell that cannot be detected with
the immunochemical method used, and that is repairable and
less toxic to the cell than, for instance, the Pt-GG adduct.
Formation of such an adduct might prevent the production
of more toxic adducts; in combination with differences in cell
cycle characteristics this might explain the resistance.
Speculations on the nature of this adduct might be directed
by the finding of an elevated level (2.5-fold) of total GSH in
GLC4-CDDP (Hospers et al., 1988). This might give rise to
the formation of a GSH-Pt-DNA adduct as described by
Eastman (1987).
Additional experiments are necessary to analyse further
these differences in adduct formation and their possible role
in resistance.
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